Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug458 | Azithromycin 500Mg Oral Tablet Wiki | 0.50 |
| drug3609 | Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Wiki | 0.50 |
| drug228 | Ad5-nCoV Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug234 | Adenovirus Type-5 Vectored COVID-19 Vaccine Wiki | 0.50 |
| drug4833 | artus Influenza A/B RT-PCR Test Wiki | 0.50 |
| drug454 | Azithromycin (Azithro) Wiki | 0.50 |
| drug3248 | Placebo for Hydroxychloroquine Wiki | 0.50 |
| drug3247 | Placebo for Azithromycin Wiki | 0.50 |
| drug1789 | Glucose tablets Wiki | 0.50 |
| drug1964 | Hydroxychloroquine 200 Mg Oral Tablet Wiki | 0.35 |
| drug986 | Cholecalciferol Wiki | 0.22 |
| drug1951 | Hydroxychloroquine (HCQ) Wiki | 0.22 |
| drug453 | Azithromycin Wiki | 0.16 |
| drug2230 | Ivermectin Wiki | 0.10 |
| drug1950 | Hydroxychloroquine Wiki | 0.05 |
| drug3195 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003384 | Coxsackievirus Infections NIH | 0.50 |
| D018184 | Paramyxoviridae Infections NIH | 0.29 |
| D018357 | Respiratory Syncytial Virus Infections NIH | 0.16 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 4 clinical trials
The study will be conducted using nasopharyngeal swab specimens collected prospectively from individuals suspected of having the signs and symptoms of an acute respiratory tract infection caused by a respiratory virus. A series of standard viral culture tests validated for routine use in the clinical laboratory, and/or a series of PCR-based Laboratory Developed Tests (PCR-LDT) validated by a central reference laboratory will be used to verify the performance of the investigational artus Influenza A/B RT-PCR test and the QIAGEN ResPlex II Advanced Panel test. From each specimen five (5) aliquots will be prepared: (a) one aliquot will be tested in real-time using the assigned viral culture reference methods; (b) one aliquot will be used to extract nucleic acid in real-time for investigational testing; (c) one aliquot of the specimen will be stored at --70C for subsequent shipment to the reference laboratory for PCR-LDT testing, (d) one aliquot will be archived at -70C for subsequent follow-up by the reference laboratory (e.g., bi-directional sequencing of positive specimens), and (e) any remaining specimen will be stored for the Fresh vs. Frozen Study. The extracted nucleic acid generated from the second aliquot (i.e., "b" above) will be split and subjected to testing by both the artus Influenza A/B RT-PCR test and the ResPlex II Advanced Panel test.
Description: The presence of Influenza A or Influenza B virus.
Measure: Detection of Respiratory Viruses Time: Specimens will be taken within 5 days of the appearance of symptoms.This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of SARS-CoV-2.
This is a clinical trial to evaluate the safety and immunogenicity of a recombinant adenovirus 5 vectored COVID-19 vaccine (Ad5-nCoV) with two doses and with different adminstration routes in healthy adults aged 18 years and older.
Description: The occurrence of AE in all groups within 0-7 days after each vaccination;
Measure: Incidence of the AE in all groups Time: 0-7 days after each vaccinationDescription: Seroconversion rate the IgG antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Seroconversion rate of the IgG antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Geomean titers of the IgG antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Geomean titers of the IgG antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Geomean titers of the neutralizing antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Geomean titers of the neutralizing antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: The occurrence of AE in all groups within 0-30 minutes and 0-28 days after each vaccination.
Measure: Incidence of the AE in all groups Time: 0-30 minutes, 0-28 days after each vaccinationDescription: The occurrence of Serious adverse events (SAE) in all groups within 6 months after the final vaccination.
Measure: Incidence of Serious adverse events (SAE) in all groups Time: 6 months after the final vaccinationDescription: Geomean titers of the IgG antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Geomean titers of the IgG antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Seroconversion rate of the IgG antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Seroconversion rate of the IgG antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Geomean titers of the neutralizing antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Geomean titers of the neutralizing antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 0, Day14, Day 28 or Day 56 after first vaccination and on day 14, day 28 and day168 after last vaccination.
Measure: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.Description: The positive rate of IFN-γ stimulated by S protein overlapping peptide library detected by ELISpot on Day 0 and Day 14 after each vaccination
Measure: Cellular immune response by ELISpot Time: Day 0 and Day 14 after each vaccinationDescription: Geomean titers of neutralizing antibody response to Ad5-vector on Day 0, 14 and 28 after each vaccination.
Measure: Geomean titers of neutralizing antibody response to Ad5-vector Time: Day 0, 14 and 28 after each vaccination.Description: The positive rate of the specific cytokines expressed by CD4+ and CD8+ T lymphocytes stimulated by S protein overlapping peptide library detected by intracellular cytokine staining on Day 0 and Day 14 after each vaccination
Measure: Cellular immune response by ICS Time: Day 0 and Day 14 after each vaccinationDescription: Geomean titers of the IgA antibody against SARS-CoV-2 on Day 0, 14 and 28 after each vaccination.
Measure: Geomean titers of the IgA antibody against SARS-CoV-2 Time: Day 0, 14 and 28 after each vaccinationThe 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China. It has manifest into a global health crisis with escalating confirmed cases and spread across many countries. In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of diseases caused by COVID-19 can be tough for current treatment. This study is a phase I clinical trial of booster vaccination of adenovirus type-5 vectored COVID-19 vaccine 6 months after prime vaccination. The investigators intent to evaluate the safety and immunogenicity of booster vaccination of adenovirus type-5 vectored COVID-19 vaccine in healthy adults aged aged 18-60 years.
Description: Occurrence of adverse reactions within 14 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of adverse reactions within 14 days after booster vaccination Time: 0-14 days post-vaccinationDescription: Occurrence of adverse events within 14 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of adverse events within 14 days after booster vaccination Time: 0-14 days post-vaccinationDescription: Occurrence of adverse events within 28 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of adverse events within 28 days after booster vaccination Time: 0-28 days post-vaccinationDescription: Occurrence of serious adverse events within 28 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of serious adverse events within 28 days after booster vaccination Time: 0-28 days post-vaccinationDescription: Occurrence of serious adverse events within 6 months after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of serious adverse events within 6 months after booster vaccination Time: 6 months post-vaccinationDescription: Occurrence of serious adverse events within 12 months after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of serious adverse events within 12 months after booster vaccination Time: 12 months post-vaccinationDescription: Changes in laboratory test indicators (including white blood cell count, lymphocyte count, neutrophils, platelets, hemoglobin, ALT, AST, total bilirubin, fasting blood glucose, creatinine) before and 1 day after vaccination
Measure: Changes in laboratory test indicators before and 1 day after vaccination Time: 1 day post-vaccinationDescription: Antibody of S-RBD at day 14, day 28, month 6 and month 12 after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Antibody of S-RBD at day 14, day 28, month 6 and month 12 after booster vaccination Time: 14 days, 28 days, 6 months and 12 months post-vaccinationDescription: Cellular immunity at day 14 after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Cellular immunity at day 14 after booster vaccination Time: 14 days post-vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports